|
1
|
Lee W, Belkhiri A, Lockhart AC, Merchant
N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB
and El-Rifai W: Overexpression of OATP1B3 confers apoptotic
resistance in colon cancer. Cancer Res. 68:10315–10323. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirschi B, Gallmeier E, Ziesch A,
Marschall M and Kolligs FT: Genetic targeting of B-RafV600E affects
survival and proliferation and identifies selective agents against
BRAF-mutant colorectal cancer cells. Mol Cancer. 13:1222014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan S, Peng X, Peng W, Zhao Y and Wei Y:
Enhancement of oxaliplatin-induced cell apoptosis and tumor
suppression by 3-methyladenine in colon cancer. Oncol Lett.
9:2056–2062. 2015.PubMed/NCBI
|
|
4
|
Choi JH, Won YW, Kim HS, Oh YH, Lim S and
Kim HJ: Oxaliplatin-induced sinusoidal obstruction syndrome
mimicking metastatic colon cancer in the liver. Oncol Lett.
11:2861–2864. 2016.PubMed/NCBI
|
|
5
|
Fan F, Gray MJ, Dallas NA, Yang AD, Van
Buren G II, Camp ER and Ellis LM: Effect of chemotherapeutic stress
on induction of vascular endothelial growth factor family members
and receptors in human colorectal cancer cells. Mol Cancer Ther.
7:3064–3070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Q, You T, Yuan D, Han X, Hong X, He
B, Wang L, Tong X, Tao L and Harris AL: Cisplatin and oxaliplatin
inhibit gap junctional communication by direct action and by
reduction of connexin expression, thereby counteracting cytotoxic
efficacy. J Pharmacol Exp Ther. 333:903–911. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo C, Yuan D, Li X, Yao W, Luo G, Chi X,
Li H, Irwin MG, Xia Z and Hei Z: Propofol attenuated acute kidney
injury after orthotopic liver transplantation via inhibiting gap
junction composed of connexin 32. Anesthesiology. 122:72–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Graziano AC, Parenti R, Avola R and
Cardile V: Krabbe disease: Involvement of connexin43 in the
apoptotic effects of sphingolipid psychosine on mouse
oligodendrocyte precursors. Apoptosis. 21:25–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spagnol G, Kieken F, Kopanic JL, Li H,
Zach S, Stauch KL, Grosely R and Sorgen PL: Structural studies of
the Nedd4 WW domains and their selectivity for the connexin43
(Cx43) carboxyl terminus. J Biol Chem. 291:7637–7650. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le HT, Sin WC, Lozinsky S, Bechberger J,
Vega JL, Guo XQ, Sáez JC and Naus CC: Gap junction intercellular
communication mediated by connexin43 in astrocytes is essential for
their resistance to oxidative stress. J Biol Chem. 289:1345–1354.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He B, Tong X, Wang L, Wang Q, Ye H, Liu B,
Hong X, Tao L and Harris AL: Tramadol and flurbiprofen depress the
cytotoxicity of cisplatin via their effects on gap junctions. Clin
Cancer Res. 15:5803–5810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Myers J and Shetty N: Going beyond
efficacy: Strategies for cancer pain management. Curr Oncol.
15:(Suppl 1). S41–S49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sirnes S, Bruun J, Kolberg M, Kjenseth A,
Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E and
Rivedal E: Connexin43 acts as a colorectal cancer tumor suppressor
and predicts disease outcome. Int J Cancer. 131:570–581. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Liu B, Wang Q, Yuan D, Yang Y,
Hong X, Wang X and Tao L: Propofol depresses the cytotoxicity of
X-ray irradiation through inhibition of gap junctions. Anesth
Analg. 112:1088–1095. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan DD, Chi XJ, Jin Y, Li X, Ge M, Gao
WL, Guan JQ, Zhang AL and Hei ZQ: Intestinal injury following liver
transplantation was mediated by TLR4/NF-κB activation-induced cell
apoptosis. Mol Med Rep. 13:1525–1532. 2016.PubMed/NCBI
|
|
17
|
Yuan D, Sun G, Zhang R, Luo C, Ge M, Luo G
and Hei Z: Connexin 43 expressed in endothelial cells modulates
monocyte-endothelial adhesion by regulating cell adhesion proteins.
Mol Med Rep. 12:7146–7152. 2015.PubMed/NCBI
|
|
18
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alcindor T and Beauger N: Oxaliplatin: A
review in the era of molecularly targeted therapy. Curr Oncol.
18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Howells LM, Sale S, Sriramareddy SN,
Irving GR, Jones DJ, Ottley CJ, Pearson DG, Mann CD, Manson MM,
Berry DP, et al: Curcumin ameliorates oxaliplatin-induced
chemoresistance in HCT116 colorectal cancer cells in vitro and in
vivo. Int J Cancer. 129:476–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ekblad L, Kjellström J and Johnsson A:
Reduced drug accumulation is more important in acquired resistance
against oxaliplatin than against cisplatin in isogenic colon cancer
cells. Anticancer Drugs. 21:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Huang XF, Qiao L and Katsifis A:
Insulin caused drug resistance to oxaliplatin in colon cancer cell
line HT29. J Gastrointest Oncol. 2:27–33. 2011.PubMed/NCBI
|
|
23
|
Peng L, Zhu H, Wang J, Sui H, Zhang H, Jin
C, Li L, Xu T and Miao R: MiR-492 is functionally involved in
Oxaliplatin resistance in colon cancer cells LS174T via its
regulating the expression of CD147. Mol Cell Biochem. 405:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
To KK, Poon DC, Wei Y, Wang F, Lin G and
Fu LW: Data showing the circumvention of oxaliplatin resistance by
vatalanib in colon cancer. Data Brief. 7:437–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Segretain D, Decrouy X, Dompierre J,
Escalier D, Rahman N, Fiorini C, Mograbi B, Siffroi JP, Huhtaniemi
I, Fenichel P and Pointis G: Sequestration of connexin43 in the
early endosomes: An early event of Leydig cell tumor progression.
Mol Carcinog. 38:179–187. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leithe E, Sirnes S, Omori Y and Rivedal E:
Downregulation of gap junctions in cancer cells. Crit Rev Oncog.
12:225–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanson M, Marcaud V, Robin E, Valery C,
Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two
rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fossepre M, Leherte L, Laaksonen A and
Vercauteren DP: On the modularity of the intrinsic flexibility of
the µ opioid receptor: A computational study. PloS One.
9:e1158562014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katritch V, Cherezov V and Stevens RC:
Structure-function of the G protein-coupled receptor superfamily.
Annu Rev Pharmacol Toxicol. 53:531–556. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu W, Wei N, Jiang CN, Cui S and Yuan J:
Effects of sufentanil on human gastric cancer cell line SGC-7901 in
vitro. Cent Eur J Immunol. 39:299–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
